medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2017, Number 5

<< Back Next >>

Rev ADM 2017; 74 (5)

Pharmacological therapy and therapeutic advances in xerostomy and hyposalivation

Rodríguez PJI, Martínez SG, Rodríguez FNI, Chapa AMG, Solís SJM

Language: Spanish
References: 26
Page: 221-223
PDF size: 168.23 Kb.


ABSTRACT

Saliva plays a determinant role in the maintenance and function of oral tissues, where a decrease in salivary flow levels leads to hyposalivation or hyposialia, bringing with it a series of characteristics that provide an ideal environment for the installation of opportunistic microorganisms and conditions harmful to the oral and systemic health of patients. Today there are many causes that lead to hyposialia, including Sjögren’s syndrome, external beam radiotherapy, among others, which have been tested by pharmacological sialogogs such as pilocarpine, cevimelin, betanecol and carbacoline, in addition to therapeutic alternatives to reverse the signs obtained by hyposalivation and to mitigate the symptoms of xerostomia. The objective of the present is to make a review of the literature on the pharmacological treatment in hyposalivation and xerostomia in Sjögren’s syndrome and external beam radiotherapy.


REFERENCES

  1. Löfgren CD, Wickström C, Sonesson M, Lagunas PT, Christersson C. A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health. 2012; 12: 29.

  2. Banderas JA, González M, Sánchez M, Millán E, López A, Vilchis A. Flujo y concentración de proteínas en saliva total humana. Salud Publica Mex. 1997; 39 (5): 433-443.

  3. Falcão DP, da Mota LM, Pires AL, Bezerra AC. Sialometry: aspects of clinical interest. Rev Bras Reumatol. 2013; 53 (6): 525-531.

  4. Chapa-Arizpe G, Garza-Salinas B, Garza-Enríquez M, Martínez-Sandova G. Hiposalivación y xerostomía; diagnóstico, modalidades de tratamiento en la actualidad: aplicación de neuroelectroestimulación. Rev Mex Periodontol. 2012; 3 (1): 38-46.

  5. Silvestre-Donat FJ, Miralles-Jordá L, Martínez-Mihi V. Tratamiento de la boca seca: puesta al día. Med Oral Patol Oral Cir Bucal. 2004; 9 (4): 273-279.

  6. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer. 2010; 18 (8): 1061-1079.

  7. Rodríguez J, Martínez G, Rodríguez, N, Chapa M, Solís J. Dental perspective on Sjögren’s syndrome: literature review. J Oral Res. 2015; 4 (3): 211-222.

  8. Babaee N, Gholizadehpasha A, Zahedpasha S, Moghadamnia Y, Zamaninejad S, Moghadamnia AA. Effects of milk curd on saliva secretion in healthy volunteer compared to baseline, 2% pilocarpine and equivalent pH adjusted acetic acid solutions. Indian J Dent Res. 2011; 22 (4): 547-551.

  9. Bernardi R, Perin C, Becker FL, Ramos GZ, Gheno GZ, Lopes LR et al. Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res. 2002; 35 (1): 105-110.

  10. Nakamura N, Sasano N, Yamashita H, Igaki H, Shiraishi K, Terahara A et al. Oral pilocarpine (5mg t.i.d.) used for xerostomia causes adverse effects in Japanese. Auris Nasus Larynx. 2009; 36 (3): 310-313.

  11. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL 3rd, Tran-Johnson TK et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999; 159 (2): 174-181.

  12. Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan--a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006; 105 (10): 796-803.

  13. Peluso G, De Santis M, Inzitari R, Fanali C, Cabras T, Messana I et al. Proteomic study of salivary peptides and proteins in patients with Sjögren’s syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007; 56 (7): 2216-2222.

  14. Rhodus NL, Liljemark W, Bloomquist C, Bereuter J. Candida albicans levels in patients with Sjögren’s syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study. Quintessence Int. 1998; 29 (11): 705-710.

  15. Rodríguez J, Sánchez R, Garza M, Nakagoshi M, Solis J, Arévalo K et al. Salivary stimulation by prolonged release of pilocarpine using films in diabetic rats. J Oral Res. 2015; 4 (2): 103-108.

  16. Rodríguez J, Sánchez R, Garza M, Nakagoshi M, Solís J, Arévalo K et al. Physicochemical and antimicrobial evaluation of chitosan and hydroxypropyl methylcellulose films for prolonged release of pilocarpine. J Oral Res. 2015; 4 (1): 25-31.

  17. Rodríguez-Pulido J, Martínez-Sandoval G, Rodríguez-Franco N, Chapa-Arizpe M, Riega-Torres J, Garza-Elizondo M. Salivary stimulation by prolonged release of pilocarpine in Sjögren’s syndrome. J Oral Res. 2017; 6 (3): 64-69.

  18. Fernández RG, Cortés NZ, Ochoa FJ, Poitevin MA, Pérez HE. Respuesta terapéutica de la pilocarpina en relación a la xerostomía inducida por radioterapia. Rev Odontológica Mex. 2008; 12 (3): 149-153.

  19. Fuertes S, Setoain X, Rovirosa A, Mateos J, Fuster D, Ferre J et al. Utilidad de la pilocarpina como profiláctico de xerostomía en pacientes con cáncer de cabeza y cuello tratados con radioterapia. Valoración mediante gammagrafía y flujo salivar. Rev Esp Med Nucl. 2004; 23 (4): 259-266.

  20. Coaccioli S, Landucci P. Cevimeline for the treatment of dry mouth in patients with Sjogren’s syndrome. Clin Med Insights Ther. 2009; 1 (1): 104-109.

  21. Voskoboynik B, Babu K, Hack JB. Cevimeline (Evoxac®) overdose. J Med Toxicol. 2011; 7 (1): 57-59.

  22. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002; 46 (3): 748-754.

  23. Suzuki K, Matsumoto M, Nakashima M, Takada K, Nakanishi T, Okada M et al. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology. 2005; 74 (2): 100-105.

  24. Takakura K, Takaki S, Takeda I, Hanaue N, Kizu Y, Tonogi M et al. Effect of cevimeline on radiation-induced salivary gland dysfunction and AQP5 in submandibular gland in mice. Bull Tokyo Dent Coll. 2007; 48 (2): 47-56.

  25. Omori Y, Asari T, Maruyama K, Kusama H, Kojima M, Shibata N. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. Arzneimittelforschung. 2003; 53 (5): 342-350.

  26. Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2014; 32 (4): 575-577.




2020     |     www.medigraphic.com